Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 24;15(9):1240–1250. doi: 10.2215/CJN.15931219

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 by the American Society of Nephrology

PMC Copyright notice

Figure 3. — Relative ratios of urine biomarkers by CA-AKI status in this study are less than those in the Marathon study and the Translational Research Investigating Biomarker Endpoints in AKI (TRIBE-AKI) study. Comparison of the relative ratio of urine biomarkers in two cohorts: the Prevention of Serious Adverse Events following Angiography (PRESERVE) trial and the Marathon study. The PRESERVE trial compares urine biomarker levels before and 2–4 hours postangiography in patients who did and did not develop CA-AKI. The Marathon study compares urine biomarker levels 24 hours premarathon to 30 minutes postmarathon. The TRIBE-AKI study compared urine biomarkers before and 0–6 hours after cardiac surgery. The relative ratios of urine biomarkers in the PRESERVE trial are substantially lower than the ratios of urine biomarkers in the marathon runners and in patients undergoing cardiac surgery. The relative biomarker ratio was truncated at 30 for the Marathon study results to facilitate the visual comparison across studies. In the AKI group, the 75th percentiles >30 are urine KIM-1 (105.04), urine NGAL (48.38), urine IL-18 (43.86), and urine MCP-1 (188.71). The median for MCP-1 is 60.84.